Aldo-Keto Reductase Family 7 Member A3 (AKR7A3) is a member of the aldo-keto reductase (AKR) superfamily, which consists of NAD(P)H-linked oxidoreductases. These enzymes primarily catalyze the reduction of aldehydes and ketones to their respective primary and secondary alcohols . AKR7A3 is also known as aflatoxin aldehyde reductase and is involved in the detoxification of harmful aldehydes and ketones .
AKR7A3 is a protein-coding gene that produces an enzyme capable of reducing the dialdehyde protein-binding form of aflatoxin B1 (AFB1) to the non-binding AFB1 dialcohol . This reduction process is crucial for protecting the liver against the toxic and carcinogenic effects of AFB1, a potent hepatocarcinogen . The enzyme is active over a broad pH range, with an optimum at pH 6.6 .
The AKR7A3 enzyme plays a significant role in the detoxification of aldehydes and ketones generated during drug metabolism and xenobiotic metabolism . It is involved in various metabolic pathways, including the biotransformation of aflatoxin B1, a toxic fungal metabolite . The enzyme’s ability to detoxify harmful compounds highlights its importance in protecting the liver and other tissues from damage.
Mutations or alterations in the expression of AKR7A3 have been associated with various diseases. For instance, AKR7A3 has been linked to conditions such as congenital symmetric circumferential skin creases and multiple benign circumferential skin creases on limbs . Additionally, the enzyme’s role in detoxifying carcinogens like aflatoxin B1 underscores its potential impact on cancer prevention and treatment.
Research on AKR7A3 has focused on understanding its structure, function, and regulation. Studies have demonstrated the enzyme’s activity against various substrates, including 4-nitrobenzaldehyde and 9,10-phenanthrenequinone . The enzyme’s broad substrate specificity and detoxification capabilities make it a potential target for therapeutic interventions aimed at mitigating the effects of toxic aldehydes and ketones.